Research Article
Use of Drugs Associated with QT Interval Prolongation at the Hospital Level during the COVID-19 Pandemic in Colombia
Table 2
Distribution of use of each pharmacological group of QT-prolonging drugs.
| Medication group | Total patients () | % within the QT group |
| Nervous system | 224140 | 63.0 | Opioids | 164651 | 46.3 | Anesthetics, general | 62951 | 17.7 | Psychotropic drugs (antiparkinson drugs, psycholeptics, and psychoanaleptics) | 39582 | 11.1 | Alimentary tract and metabolism | 202046 | 56.8 | Anti-infectives for systemic use | 46238 | 13.0 | Antibacterials for systemic use | 35683 | 10.0 | Antimycotics for systemic use | 3611 | 1.0 | HIV (antivirals for systemic use) | 556 | 0.2 | Cardiovascular system | 41564 | 11.7 | Diuretics | 40098 | 11.3 | Antiarrhythmics | 3794 | 1.1 | Systemic hormonal preparations, excluding sex hormones | 30850 | 8.7 | Respiratory system | 9376 | 2.6 | Antiparasitic products, insecticides, and repellents | 4051 | 1.1 | Antimalarials | 1308 | 0.4 | Antineoplastic and immunomodulating agents | 1513 | 0.4 | Blood and blood-forming organs | 157 | 0.0 | Musculoskeletal system | 57 | 0.0 | Genito-urinary system and sex hormones | 61 | 0.0 | Total | 355574 | 100.0 |
|
|